![Paul Clancy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paul Clancy
Chairman at
SIONNA THERAPEUTICS, INC.
Net worth: 3 M $ as of 2026-10-30
Profile
Mr. Paul J.
Clancy is an Independent Non-Executive Chairman at Sionna Therapeutics, Inc., an Independent Director at Incyte Corp.
and a Secretary, Director & Vice President at Stromedix, Inc. He is on the Board of Directors at Incyte Corp.
and Stromedix, Inc. Mr. Clancy was previously employed as an Independent Director by EXACT Sciences Corp., a Chairman by Xilio Therapeutics, Inc., an Executive Vice President by Alexion Pharmaceuticals, Inc., an Independent Director by Agios Pharmaceuticals, Inc., a Chief Financial Officer & Executive Vice President by Biogen Idec New Ventures, Inc., a Chief Financial Officer & Executive VP-Finance by Biogen, Inc., a VP & General Manager-Great West Business Unit by PepsiCo, Inc., a Senior Vice President-Finance by Biogen Idec, Inc. (North Carolina), and a President & Director by Bioverativ Therapeutics, Inc. He received his undergraduate degree from Babson College and an MBA from Columbia Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INCYTE CORPORATION 0.01% | 2026-09-29 | 25,838 ( 0.01% ) | 3 M $ | 2026-10-30 |
| 2026-06-16 | 0 ( -.--% ) | - $ | 2026-10-30 |
Paul Clancy active positions
| Companies | Position | Start |
|---|---|---|
| SIONNA THERAPEUTICS, INC. | Chairman | 2022-06-05 |
| INCYTE CORPORATION | Director/Board Member | 2015-01-19 |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Director/Board Member | - |
Former positions of Paul Clancy
| Companies | Position | End |
|---|---|---|
| EXACT SCIENCES CORPORATION | Director/Board Member | 2026-03-22 |
| XILIO THERAPEUTICS, INC. | Chairman | 2026-01-05 |
| AGIOS PHARMACEUTICALS, INC. | Director/Board Member | 2023-06-12 |
| ALEXION PHARMACEUTICALS, INC. | Director of Finance/CFO | 2019-10-31 |
| BIOGEN INC. | Director of Finance/CFO | 2017-06-12 |
Education of Paul Clancy
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
85
1st degree connections
14
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
PepsiCo, Inc.
 PepsiCo, Inc. Food: Specialty/CandyConsumer Non-Durables Makes, markets, distributes and sells beverages & convenient food products | Consumer Non-Durables |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
EXACT Sciences Corp.
 EXACT Sciences Corp. Medical SpecialtiesHealth Technology Develops proprietary technologies for the detection of cancer | Health Technology |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Health Technology |
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Babson College
 Babson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Columbia Business School
 Columbia Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
- Stock Market
- Insiders
- Paul Clancy
